BGC 200761

Drug Profile

BGC 200761

Alternative Names: BGC-20-761; BGC20-0761

Latest Information Update: 08 Apr 2008

Price : $50

At a glance

  • Originator BTG
  • Class Antipsychotics; Nootropics
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Schizophrenia

Most Recent Events

  • 08 Apr 2008 Preclinical development is ongoing
  • 08 Apr 2008 BTG is still seeking partnership opportunities for BGC 200761 (http://www.btgplc.com)
  • 05 Mar 2004 Preclinical trials in Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top